Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAmeriHealth Caritas Tumor Fields Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentAmeriHealth CaritasPolicy CCP.1568

    Tumor Treating Fields for Pancreatic Cancer

    Customize your policy alerts

    Sign up for AmeriHealth Caritas Policy CCP.1568 alerts

    Get alerted when Policy CCP.1568 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage determinations for tumor treating fields used to treat pancreatic cancer. It applies to providers submitting claims for the service or related equipment under AmeriHealth Caritas, subject to applicable benefits, laws, and plan terms.

    Policy Summary
    PayerAmeriHealth Caritas
    PolicyTumor Treating Fields for Pancreatic Cancer
    Policy CodePolicy CCP.1568
    Change TypeNo material change
    Effective DateSep 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateDec 1, 2027
    Key ActionClaims for tumor treating fields for unresectable, locally advanced pancreatic cancer may be denied as investigational and not medically necessary.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not coveredCoverage stance for tumor treating fields in unresectable, locally advanced pancreatic cancer
    571Participants in the PANOVA-3 phase III trial

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~2 monthsReported incremental survival gain with tumor treating fields plus chemotherapy
    76.3%Participants experiencing device-related skin adverse events
    $1.0M/QALYIncremental cost-effectiveness ratio from the American payer perspective

    Medical Necessity Criteria

    Unresectable, locally advanced pancreatic cancer

    Tumor treating fields for treatment of unresectable, locally advanced pancreatic cancer are investigational/not clinically proven and therefore not medically necessary.

    Not medically necessary: Tumor treating fields are used to treat unresectable, locally advanced pancreatic cancer.

    This use is classified as investigational/not clinically proven and not medically necessary.

    Tumor treating fields for the treatment of unresectable, locally advanced pancreatic cancer are considered investigational, not clinically proven, and therefore not medically necessary under this policy.

    Related Codes

    Related codesmixed
    1025TAlternating electric fields dosimetry and delivery-simulation modeling, creation and selection of patient-specific array layouts, and placement verification.
    A4555Electrode/transducer for use with electrical stimulation device used for cancer treatment, replacement only.
    E0766Electrical stimulation device used for cancer treatment, includes all accessories, any type.

    Provider Coverage Guidance

    Denial Risk

    Claims may be denied

    Tumor treating fields for the treatment of unresectable, locally advanced pancreatic cancer are considered investigational, not clinically proven, and not medically necessary. Claims for this use may be denied.

    Clinical and Technology Background

    Tumor treating fields are low-energy, non-ionizing alternating electric fields intended to disrupt the division of cancer cells. Optune Pax is a portable device that delivers 150 kHz fields to the abdomen through non-invasive, electrically insulated transducer arrays. The U.S. Food and Drug Administration approved Optune Pax for adults with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel; however, this policy considers the treatment investigational and not medically necessary for unresectable, locally advanced disease.

    Key Terms

    Tumor treating fields
    Field typeLow-energy, non-ionizing electrical fields
    Primary purposeDisrupt cancer cells’ ability to grow and divide
    Also calledAlternating electric fields
    Optune Pax
    Device typePortable, wearable device
    Field deliveryDelivers tumor treating fields at 150 kHz
    Treatment siteAbdomen

    Therapy Line Criteria

    First-line Therapy Criteria

    The following describes the studied line of therapy; this use is not covered because it is classified as investigational/not clinically proven and not medically necessary.

    Front-line therapy: Tumor treating fields are used in combination with gemcitabine and nab-paclitaxel as front-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.

    The PANOVA-3 trial evaluated this combination as front-line treatment; the policy does not cover this use.

    Treatment Regimen Details

    IndicationRegimenCoverage
    Adult patients with locally advanced pancreatic cancer, including unresectable, locally advanced pancreatic adenocarcinomaOptune Pax tumor treating fields concomitant with gemcitabine and nab-paclitaxelNot covered — investigational/not clinically proven and not medically necessary
    Policy Summary
    PayerAmeriHealth Caritas
    PolicyTumor Treating Fields for Pancreatic Cancer
    Policy CodePolicy CCP.1568
    Change TypeNo material change
    Effective DateSep 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateDec 1, 2027
    Key ActionClaims for tumor treating fields for unresectable, locally advanced pancreatic cancer may be denied as investigational and not medically necessary.
    SourceLink
    On This Page
    Medical Necessity CriteriaRelated CodesProvider Coverage GuidanceClinical and Technology BackgroundKey TermsTherapy Line CriteriaTreatment Regimen Details
    Delivery method
    Non-invasive, electrically insulated transducer arrays connected to the device